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Background: In this paper, we modify our previously developed conjoint tumor-normal
cell model in order to make a distinction between tumor cells that are responsive to
chemotherapy and those that may show resistance.
Results: Using this newly developed core model, the evolution of three cell types:
normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical
simulations. In addition, we illustrate critical factors that cause different dynamical patterns
for normal and tumor cells. Among these factors are the co-dependency of the
normal and tumor cells, the cells’ response mechanism to a single or multiple
chemotherapeutic treatment, the drug administration sequence, and the treatment
starting time.
Conclusion: The results provide us with a deeper understanding of the possible
evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer
progression, which may contribute to improving the therapeutic strategies.
Keywords: Cancer modeling, Cellular aging, Conjoint cell growth, Chemotherapy, Drug
resistanceIntroduction
Assessing the evolution of cancer, in the presence of surrounding normal cells, is the
subject of many biomedical studies. Recently reported evidence strongly indicates that
the dynamics of tumor cells and the surrounding normal cells are not independent of
each other and may be mutually tuned [1-8]. Examination of the coupled population
dynamics of tumor and normal cell populations can potentially provide substantial
knowledge that may contribute to the identification of more effective therapeutic inter-
ventions, particularly in aging populations. Among the variety of research papers in
this field, many are based on the analysis of mathematical and computational models.
In many of these models, the growth of normal and tumor cells are considered to be
independent and are expressed by such functions as the Gompertz, the logistic, and
the exponential equations [9-13]. However, the mutual interaction of tumor cells with
surrounding normal cells, which was first mathematically introduced in a conjoint
model by Witten [14], could shed light on some of the complex patterns that can be
detected during cancer progression [15-17].
The interaction of tumor and normal cells is not the exclusive factor causing differ-
ent dynamical patterns during cancer progression, The interaction of cells with the© 2015 Shojania Feizabadi and Witten; licensee BioMed Central. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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any other therapeutic interactions are additional factors which can influence the evolu-
tion patterns of the cell populations [18-33].
While researchers continuously improve cancer treatment strategies, one of the most
serious obstacles in cancer treatment are related to drug resistance, where the chemother-
apeutic treatments do not lead to the hoped for outcome. The issues related to the drug
resistance have been broadly studied from a variety of different perspectives [34-38].
This work aims to contribute to a deeper understanding of drug resistance effects on
cancer progression through the analysis of a new mathematical model and its concomi-
tant computational simulation for a coupled tumor-normal cell framework that is more
aligned with experimental evidence. To simulate the population evolution of our model,
we have used Mathematical V7.0. Model parameter values are estimated based on values
previously introduced in the literature and are given in Table 1 of this paper. Additionally,
the other parameters in some parts are varied in order to study the system’s evolution.
This paper is structured as follows: in The basic conjoint tumor-normal cell model
Section, we briefly review the normal-tumor cell conjoint model. In Conjoint core
model in a chemo-resistance setting section, we introduce the drug resistance assump-
tions and subsequently modify the conjoint model to make a distinction between
tumor-responsive and tumor-resistant cells. In Chemo-treatment strategies in a resist-
ance setting section, we include the effects of chemotherapeutic treatment to the modi-
fied conjoint model and we examine and discuss the dynamics of the system. We
conclude and examine future research directions.
The basic conjoint tumor-normal cell model
Feizabadi & Witten [28] extended the earlier work of Witten [17] proposing the follow-
ing generalized model to describe the inter-connection between normal and tumor
cells. The core model equation system is given by:
dT tð Þ
dt
¼ rTT 1− TKT
 
þ f T Nð Þ 1að Þ
dN tð Þ
dt
¼ rNN 1− NKN
 
þ f N Tð Þ 1bð ÞTable 1 Table of parameters: parameters used in simulations have been estimated based
on the values introduced in following sources
Parameter Units Description Estimated value Reference source
rT Time
−1 Growth rate for the drug sensitive tumor cells 0.3 [31]
KT Cells Carrying capacity of tumor cells 1.2×10
6 [31]
β Time−1 Normal-tumor cell interaction rate 1 [31]
ρ0 Cells Interaction clearance term 1 [31]
ρ1 Cells Half-saturation for interaction 1000 [31]
rN Time
−1 Growth rate for the normal cells 0.4 [31]
KN Cells Carrying capacity of normal cells 10
6 [31]
κ Time−1 Tumor-normal cell interaction rate 0–0.028 [31]
T* Cells Critical size of tumor 3×105 [31]
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t, the total number of normal cells at time t, the carrying capacity for the tumor cells,
the carrying capacity for the normal cells, and the per capita growth rate for the tumor
and normal cells, and fT(N), fN(T) are the functional rules relating normal-to-tumor
and tumor-to-normal interaction respectively [39]. Witten and Feizabadi [28] have
shown that one possible set of coupled, nonlinear equations for the tumor-normal cell
system may be expressed follows:
dT tð Þ
dt






; T 0ð Þ ¼ T 0 2að Þ
dN tð Þ
dt
¼ rNN 1− NKN
 
þ κT 1− T
T 
 
; N 0ð Þ ¼ N0 2bð Þ
where T, N, KT, KN, rT, rN are previously defined. In each equation, the second terms
represent the interaction between tumor and normal cells. Here, β and κ have the units
of 1/time. Also, for consistency, ρ0 and ρ1 have units of cells. T* is the critical size of
the tumor and as the size of tumor exceeds the critical size, the normal cells growth
rate decreases. Figure 1(a) illustrates the time evolution of normal and tumor cells in a
hypothetical environment in which they grow independently (uncoupled) from one an-
other, and where each cell population follows a Gompertzian-like behavior. In this fig-
ure the growth parameters are considered to be identical for both normal and tumor
cells. In Figure 1(b) and 1(c), the conjoint growth is added to the model. As can be seen
by the different parameter values, the growth of the normal and tumor cells can be af-
fected as a result of the cellular interactions. The ability of tumor cells to inhibit the
normal cell’s growth increases as the population of tumor cells passes the critical value
T. In Figure 1(c) the growth of tumor cells is delayed due to the influence of the sur-
rounding normal cells introduced by a higher value for the interaction parameter β.
Figure 1(d) illustrates the case in which the normal cells have died out as a result of the
strong interaction effect from the tumor cells. These results are not surprising as this is
essentially a competitive exclusion model.
In the next portion of the paper we consider a modified conjoint model in which we
make a distinction between the group of tumor cells that are responsive to one type of
chemotherapeutic agent and those which are resistant to that same chemotherapeutic
agent.
Mathematical models and results
Conjoint core model in a chemo-resistance setting
One of the ongoing challenges to maximizing chemotherapeutic success in cancer
treatment is the long-standing challenge of tumor cell resistance to single or multiple
drug cocktails [40]. This mechanism, known as chemo-resistance, is complex and de-
pends upon many factors including but not limited to the specific drug, specific tumor,
or the specific host’s defense mechanism [41]. Coupled with chemo-resistance is the
challenge of age-related sensitivity or insensitivity to various drug cocktails. Thus, a
dose that might not be lethal in a 20 year-old patient could well be lethal in a 60 year-
old patient.
Drug resistance is classified into three major categories. The first category is associ-
ated with pharmacologic resistance or when the drug cannot effectively reach the
b)a)
d)c)




























































Figure 1 Blue curve: Evolution of normal cells. Red curve: Evolution of tumor cells. In this figure
the blue curve illustrates the evolution of the normal cell population and the red curve illustrates the
evolution of tumor cell population. The horizontal dashed line represents the magnitude of the critical
population of tumor cells T*; a) In this figure, the normal and the tumor cells grow, uncoupled following
a Gompertzian law. KT = KN = 1.1*10
6; rT = 0.4; rn = 0.4;T
*
C = 3*10
5; b) In this figure, the normal and the
tumor cells grow conjointly using the following parameter values β = 1;ρ0 = 1;ρ1 = 1000; κ =0.028. In this
case, the tumor cells can now suppress the growth behavior of normal cells. The population of the
normal cells declines as the population magnitude of the tumor cells passes the critical value of
T*C = 3*10
5 (the horizontal dashed line). The inhibition time in which the normal cells begin to decrease is
approximately t = 30 (unit of time); c) β = 50. In this simulation the role of normal cells on the growth of
tumor cells is significantly increased. As can be seen, the growth of tumor cells starts with a delay. As
compared with the Figure 1b, the shrinkage starts at almost t = 40. Therefore, the normal cells maintain a
higher population for a longer time. Figure 1d, expresses the evolution of normal and tumor cells when
κ =0.039, β = 1. This time, the interaction effect of tumor cells on normal cells is increased. Under this set
of simulation conditions, the population of normal cells goes to minimum value and they die out
of system.
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in the biochemistry of the tumor cell, for example when the drugs are not active at the
tumor cell sites. The third category is when chemo-resistance results from genetic mu-
tation of the tumor cells [42,43].
In order to overcome drug resistance, we need to improve treatment efficacy by bet-
ter understanding the resistance mechanisms and their effect on the cancer progres-
sion. This is a complex challenge and, so far has remained beyond traditional clinical
and experimental examination. The complexity of the problem has led investigators to
further develop their understanding using modeling and simulation methods. In fact,
this challenge has been the subject of many theoretical and computational studies
[44-51]. In the upcoming section of the paper we focus on this problem by introducing
a chemo-resistant tumor cell component to our model. We modify the model as
follows.
First, we rely on reported evidence indicating that metastatic tumors with larger sizes
are more likely to show resistance to chemotherapeutic drugs [52,53]. Therefore, the
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Consequently, we have assumed that the second term is equation 2a is ignorable. For
the purposes of discussion, we have assumed that the drug resistant tumor cells are
created as a result of tumor cell mutation. They become resistant tumor cells with a
mutation rate μ [42]. Further, we assume that the drug resistant tumor cells also grow
under the logistic growth law where the population growth rate, rR, is modified by the
density dependent term associated to the total number of tumor cells. In our model, KR
is the carrying capacity for the drug resistant tumor cells. Lastly, we remember that the
population of the normal cells is controlled by the tumor cell population. Combining
all of these assumptions along with our earlier model equations, we obtain the follow-
ing new equation system:
dT tð Þ
dt
¼ rTT 1−T þ TRKT
 
−μT tð Þ; T 0ð Þ ¼ T0 3að Þ
dTR tð Þ
dt
¼ rRTR 1−T þ TRKR
 
þ μT tð Þ; TR 0ð Þ ¼ TR0 3bð Þ
dN tð Þ
dt
¼ rNN 1− NKN
 
þ κ T þ TRð Þ 1−T þ TRT 
 
: N 0ð Þ ¼ N0 3cð Þ
The behavior of the normal, drug sensitive tumor, and drug resistant tumor cells issimulated in Figure 2. Understanding the evolution of each component becomes more
critical in connection with the treatment of the system with chemotherapeutic agents
that will be discussed in the next section.
In the drug resistance model, as the population of total tumor cells which now in-
cludes both the responsive and the resistant tumor cells, passes the critical value T* the
normal cell population decreases in number. In Figure 2(a) the growth rate of both the
drug responsive and the resistant tumor cells are considered to be identical. In this case
the population of the resistant tumor cells is larger due to the fact that mutation of re-
sponsive tumor cells continually decreases the population of the responsive tumor cell
population and subsequently increases the size of the resistant tumor cell population.
In Figure 2(b), the growth rate of responsive tumor cells is higher than that of the re-
sistant tumor cells. Here, we can see that for a period of time, the population of the re-
sponsive tumor cell population is larger. However, ultimately the population of the
drug resistant tumor cells becomes higher than that of the tumor responsive cells. In
Figure 2(c), the tumor-normal cell coupling coefficient is increased slightly. Under this
new condition, the population of normal cells has become smaller than the critical
value, T* = 5*105. Therefore, the tumor cells overwhelm the normal cells and the nor-
mal cells die out of the system faster than before, In addition, the population of the
drug resistant tumor cells continues to grow. We next consider the effect of adding a
chemotherapeutic agent to our system.
Chemo-treatment strategies in a resistance setting
The conjoint model, in the presence of the chemo-resistant tumor cells, may also be
modified to consider the introduction of chemotherapeutic agents. To systematically
investigate the evolution of the cells, we have simulated the system’s dynamics under
the following conditions. We first assume that due to the drug resistance, the first che-

















































Figure 2 The evolution of normal cells and tumor cells in a chemo-resistance setting. In this figure
the blue curve illustrates the evolution of normal cell population, red curve illustrates the evolution of the
drug responsive tumor cell population, and the purple curve illustrates the evolution of the drug resistant
tumor cell population. The horizontal dashed line represents the magnitude of the critical population of
tumor cells, T*. a) In this figure, normal and tumor cell populations grow in a coupled setting where the
parameter values are given by. KT = KN = KR = 10
6; rT = rr = 0.25; rn = 0.4; T
*
C = 5*10
5; κ = 0.124; μ = 5*10−3. Due
to mutation and growth, the population of drug resistant tumor cells is higher than that of the drug
sensitive tumor. Normal cell numbers decrease as the total number of tumor cells exceed the magnitude of
the critical tumor cell population. b) In this figure, rT = 0.25; rr = 0.2. Here, the population of drug responsive
tumor cells is higher at the beginning of the developmental curve. However, at approximately t = 160 days,
the system contains a higher population of drug resistance cells. c) In this figure, κ = 0.126, rT = 0.25; rr = 0.2.
Using this set of parameters we find that the population of normal cells has become smaller that critical
value of tumor cells. In such a case the normal cells die out of the system.
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tumor cells decreases following an interaction with this drug. Secondly, we have simu-
lated the dynamics of the system under a combination therapy, where the second
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the effects of the drug cocktail are studied when the time of drug administration is
varied.
As suggested by Gardner [54] and used in other studies [29,33], the drug interaction
may be structured as aϕ(1 − e
−MC)ϕ. Here, φ is the cell population number of the three
types of cells: T, TR, N. The parameter C is the concentration of the drug at the site,
M is the pharmacokinetic factor, and aφ is the response factor. The function F(C) = aϕ
(1 − e−MC) is the fraction cell kill for a given amount of drug “C”. In the presence ofb)a)
d)c)
f)e)




















































































Figure 3 The evolution of normal and tumor cells during the phase of therapy in a chemo-resistance
setting. In this figure the blue, red, and purple curves illustrate the evolution of the normal population, the drug
responsive tumor cell population, and the drug resistant tumor cell population respectively. a) The behavior of
the coupled normal-tumor cells in the absence of drug resistant tumor cells and with no chemotherapy
is simulated when KT = KN = 10
6, rT = 0.25 rn = 0.5, κ = 0.124, T*C = 5*105. b) The conjoint normal-tumor cells
are now simulated in the presence of an anti-tumor drug. The fraction killing rate is considered to be
constant with the value of a T (1-e
-MC) = 0.1, and the treatment is started at t = 50 days. It is assumed that
the administered drug has no effect on normal cells; aN (1-e
-MC) = 0. c) the drug resistance conjoint
model in which the tumor cells are categorized either as drug responsive or drug resistant is simulated
when KT = KN = KR = 1*10
6, rT = 0.25 rn = 0.5, rR = 0.1, κ = 0.124, T*C = 5*105, μ = 10−3. d) The three component
model is simulated as the system interacts with an anti-tumor drug effective only on the drug responsive tumor
cells, aT (1-e
-MC) = 0.1 at t = 50 days. e) In this figure, the dynamics of the three-component is simulated where
the system is treated with two distinct drugs, one effective only on drug responsive tumor cells and one on
the drug resistant tumor cells when aT (1-e
-MC) = 0.1 and aR (1-e
-MC) = 0.02 and both treatments are started at
t = 50. f) A similar treatment to that of Figure e is simulated at t = 5 days.
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¼ rTT 1−T þ TRKT
 
−μT tð Þ−aT 1−e−MC
 
T ; ; T 0ð Þ ¼ T0 4að Þ
dTR tð Þ
dt
¼ rRTR 1−T þ TRKR
 
þ μT tð Þ−aR 1−e−MC
 
TR; ; TR 0ð Þ ¼ TR0 4bð Þ
dN tð Þ
dt
¼ rNN 1− NKN
 




N : N 0ð Þ ¼ N0 4cð Þ
In the first two simulations, Figure 3(a,b), the conjoint tumor-normal cell population
model is simulated where there is no mutation and hence no resistant tumor cell popu-
lation. In a drug-free system, the coupling effect and the decrease in of normal cells
can be observed as the tumor cells exceed the critical value T*. This same system is
then simulated when the tumor cells interact with anti-tumor drugs and the toxicity of
the drug kills the tumor cells. As the size of tumor cells decrease, the normal cells re-
cover and subsequently return to a higher population number. In Figure 3(a-f ), the
number of normal cells increases slightly beyond the carrying capacity (KR = 1*10
6). At
this point which, for instance, can be seen around t = 50 in Figure 2(b), the tumor cell
population is less than the magnitude of the critical population, T*; therefore, the sec-
ond term of equation 4 is positive and slightly increases the population of normal cells.
In fact, normal cells react to the presence of small groups of tumor cells in the system.
In Figure 3(c), tumor cells we return to the two population tumor cell model; resist-
ant and non-resistant tumor cells. The appearance of the drug resistant tumor cells at
t ~ 50 days and their subsequent growth is illustrated in this figure. Given the mutation
rate of μ = 10−3, the population of drug responsive tumor cells decreases. However, the
population of drug resistant tumor cells increases over time as there are no chemother-
apeutic agents that target this population.
Figure 3(d) illustrates the dynamics of the cell populations when the system interacts
with an anti-tumor drug which is effective only on the drug responsive tumor cells.
The drug is administered at t = 50 days. The drug responsive tumor cells decrease and
die out of the system. Due to the chemotherapeutic treatment, the total number of
tumor cells falls below the critical size of tumor cells. Therefore, the normal cells main-
tain higher population for a period of time. However, mutated drug-resistant tumor
cells increase and their population will eventually pass the critical value. As a result,
the normal cells start to decrease again. This kind of chemotherapeutic intervention
can create a delay in possible organ failure by maintaining a higher number of normal
cells for a period of time.
In the next simulation, we introduce the combination therapy protocol. A combin-
ation therapy is considered a more effective treatment strategy with cancers that show
resistance to some of the chemotherapeutic agents. In this mode of intervention, while
the tumor is treated by the recommended chemotherapeutic drug protocol, other che-
motherapeutic drugs are also used in order to target those tumor cells that have devel-
oped defense mechanisms against the first type of chemotherapeutic agent. In Figure 3
(e) illustrate the dynamics of the system under a multiple therapeutic protocol. In this
simulation, both drugs are administered at the same time, t = 50. A lower dosage and
therefore lower toxicity is considered for the anti-resistant tumor cell population. This
mode of intervention was chosen due to the fact that, at the start of chemotherapy, drug
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considered for the non-resistant population. As can be seen in Figure 3(e), the normal ap-
pear, at first, to be stimulated by the tumor cell population growth but eventually return
to their carrying capacity value while the drug sensitive tumor cell population dies out of
the system as a result of interaction with the anti-cancer drug. In this simulation, due to
the toxicity of the second type of the introduced anti-cancer drug, the maximum popula-
tion of the drug resistant tumor cells is much smaller as compared to a case in which the
tumor is treated with only a single chemotheraputic drug (Figure 3(d)).
In Figure 3(f ), both treatments are supposed to be started simultaneously at an earlier
time; t = 5 days. As can be seen in this figure, not only have the normal cells reached
their carrying capacity, but also the growth of tumor cells has been delayed.Conclusions
This work, a modification of our previous work, focuses on examining the dynamics of in-
terconnected normal and tumor cells treated with chemotherapeutic agents, when some of
the tumor cells show chemo-resistance. We examined these dynamics using a collection of
different simulation parameters. Simulations demonstrated that in a conjoint system, nor-
mal cells enter a phase of diminished growth as the total number of tumor cells passes the
magnitude of a critical tumor cell population . To control the population of tumor cells
and the decrease of the population of normal cells, which may lead to organ failure, tumor
cells can be treated with chemotherapeutic agents. In order to overcome the drug resist-
ance, implementing a combination treatment is recommended. In a combination thera-
peutic approach, the dosage and the time of chemotherapy introduction play a critical role
in minimizing the population of tumor cells, while maintaining the maximum population
of the normal cells. According to our simulations, starting the combinatory therapy in the
early stage of the cancer progression may lead to better control of the cancer progression
as this treatment protocol can minimize the tumor cell population.
In our simulations, the growth rate and mutation rate of the cells are two other import-
ant factors that can potentially cause different evolution patterns. Another factor that
plays a significant role in the system dynamics is the dosage of the anti-tumor drugs. It is
more probable that a better response is achieved by increasing the drug dosage. However,
since a majority of the chemotherapeutic drugs are toxic to normal cells and the host im-
mune system, Consequently, the dosage and the level of toxicity must be carefully consid-
ered in order to minimize the potential damage to normal cells and to the patient.
In addition, damages that can be produced by chemotherapy are significant in the
presence of an impaired immune system. The lack of inclusion of the effects of the im-
mune system in our model is one of its limitations. Therefore, considering how the
interaction of tumor cells with the host immune system may affect tumor progression
are elements that can potentially be included in our model to achieve outcomes more
aligned with clinical and biological observations.Methods
Computational calculations
All calculations were executed on an PC using Mathematica v7.0. Code is available
from the first author.
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